CN104230833B - The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use - Google Patents
The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use Download PDFInfo
- Publication number
- CN104230833B CN104230833B CN201410526292.2A CN201410526292A CN104230833B CN 104230833 B CN104230833 B CN 104230833B CN 201410526292 A CN201410526292 A CN 201410526292A CN 104230833 B CN104230833 B CN 104230833B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- preparation
- general formula
- nitrile group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Abstract
The present invention relates to the pharmaceutical field relevant to hyperuricemia and gout.Specifically, the present invention relates to uric acid transporter body 1 inhibitor of the tetrazoleacetic acid structure of a class nitrile group-containing, its preparation method and preparing the application in diabetes medicament containing their pharmaceutical composition and they.
wherein, R
1be selected from H, C
1-C
5alkyl, C
3-C
6cycloalkyl.
Description
Technical field
The present invention relates to the pharmaceutical field that treatment hyperuricemia is relevant with gout.Specifically, the present invention relates to uric acid transporter body 1 (uratetransporter1, the URAT1) inhibitor of the tetrazoleacetic acid structure to hyperuricemia and the medicative class nitrile group-containing of gout, preparation method, containing they pharmaceutical composition and in purposes pharmaceutically.
Background technology
Gout is a kind of chronic metabolic disease, and the pain being deposited on the positions such as joint with hyperuricemia and monosodium urate salt (MSU) and causing is for principal character, and major cause is purine metabolic disturbance and/or uric acid excretion disorder.According to estimates, current global patient with gout has more than 2,000 ten thousand.The medicine being used for the treatment of gout at present comprises for lenitive anti-inflammatory drug (as colchicine etc.), suppresses uricogenesis medicine (xanthine oxidase inhibitor being representative with allopurinol and Febuxostat), thick uric acid excretion medicine (the uric acid excretion medicine being representative with probenecid, sulfinpyrazone, benzbromarone and losartan) and uriKoxidase (with pegloticase for representative).There is the toxic side effect of different degree in these medicines, as benzbromarone has the danger causing explosive hepatitis, allopurinol has liver and the untoward reaction such as bone marrow toxicity and transformation reactions, etc.
Lesinurad (RDEA594) be a kind of developed by Ardea company can suppress uric acid transporter body (uratetransporter1 in kidney, URAT1) discharged the oral pharmaceutical of uric acid in blood by the approach of urine, be in III phase clinical stage at present.The antiviral RDEA806 that Lesinurad is researched and developed by Valeant company the earliest develops.The right of ownership of present Lesinurad is at present because Ardea company is belonged to AstraZeneca by purchasing.
The invention discloses the URAT1 inhibitor of the tetrazoleacetic acid structure of a class nitrile group-containing, these compounds can be used for the medicine preparing treatment hyperuricemia and gout.
Summary of the invention
An object of the present invention is to provide one and there is excellent activity, there is a compounds of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
Another object of the present invention is to provide compound containing general formula I as effective constituent, and the medicinal compositions of one or more pharmaceutically acceptable carrier, vehicle or thinners, and the application in treatment gout.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula (I) has following structural formula:
Wherein, R
1be selected from H, C
1-C
5alkyl, C
3-C
6cycloalkyl.
Preferably, R
1be selected from H, C
1-C
3alkyl, C
3-C
4cycloalkyl.
Further, preferred following general formula (I) compound,
General formula of the present invention (I) compound is synthesized by following route:
Compound II per reacts in the presence of a base with 4-halo butyronitrile III, obtains compound IV; Compound IV in the presence of a base with R
2x (V) is obtained by reacting compound VI; Compound VI and NaN
3at NH
4there is lower reaction in Cl, obtains product VII; VII and compound 2-halogenated acetic acids VIII is obtained by reacting product I in the presence of a base.X is selected from Cl, Br and I, and described alkali is selected from various organic bases, mineral alkali etc.Described R
1definition as previously mentioned.
Compound of Formula I of the present invention has the restraining effect of URAT1, can be used as the medicine of effective constituent for the preparation of hyperuricemia and gout.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
The synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
3.36g (20mmol) Compound II per-1 and 2.96g (20mmol) compound III-1 are dissolved in the DMF of 40mL drying, stir, add 3.32g (20mmol) potassiumiodide and 6.91g (50mmol) salt of wormwood, react at 100 DEG C in nitrogen atmosphere, until reacted (TLC follows the tracks of, general 5h).After reaction mixture cooling, pour in 300mL frozen water, stir, use the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=258 ([M+Na]
+).
B. the synthesis of compound VI-1
2.82g (12mmol) compound IV-1 and 1.12g (12mmol) monobromethane V-1 are dissolved in the DMF of 30mL drying, stir, add 4.98g (36mmol) salt of wormwood, react at 100 DEG C in nitrogen atmosphere, until reacted.After reaction mixture cooling, pour in 300mL frozen water, stir, use the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid, ESI-MS, m/z=272 ([M+Na]
+).
C. the synthesis of compound VI I-1
1.99g (8mmol) compound VI-1 is dissolved in the DMF of 20mL drying, stirs, adds 1.30g (20mmol) NaN
3with 1.07g (20mmol) ammonium chloride, then react at 120 DEG C in nitrogen atmosphere, until reacted.After reaction mixture cooling, pour in 200mL frozen water, stir, use the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI I-1, white solid, ESI-MS, m/z=315 ([M+Na]
+).
D. the synthesis of Compound I-1
1.46g (5mmol) compound VI I-1 and 1.39g (10mmol) bromoacetic acid is dissolved in 15mL ethanol, stirred at ambient temperature, slowly drip the 3mL aqueous solution containing 1.20g (30mmol) NaOH, gained mixture is warming up to 50 DEG C of heating, until reacted.After reaction mixture cooling, pour in 100mL frozen water, stir, concentrated hydrochloric acid regulates pH=2-3, uses the CH of 50mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=349 ([M-H]
-).
Embodiment 2-5
With reference to embodiment 1 operation steps, prepare compound listed in Table.
Embodiment 6
The IC that compound of the present invention and related compound suppress URAT1
50be worth the similar method recorded according to document and measure (in US2014/0005136 embodiment 12).
Build the cell strain of stably express humanization URAT1 transporter: be subcloned into the plasmid pCMV6/neo (Origene) of eukaryotic expression from plasmid pCMV6-XL-5 (Origene) by humanization URAT1 gene (SLC22A112).Gene sequencing confirms humanization URAT1 consistent with the information recorded in gene pool (NM_144585.2).HEK293 human embryonic kidney cell (ATCC#CRL-1573) in EMEM tissue culture medium at the CO of 5%
2cultivate with in the air atmosphere of 95%.L2000 type transfection agents (Invitrogene) is used to be transfected on HEK293 cell by pCMV6/Neo/URAT1.After 24 hours, transfected cell being assigned to diameter is in the tissue culture dishes of 10cm, continued growth one day, then substratum is replaced by the fresh substratum containing 0.5mg/mLG418 (Gibco).After 8 days, select and collect resistance bacterium colony, and right with its test
14the transport activity of the uric acid of C-mark.By HEK293/URAT1 cell with 75, the density in 000/ hole is planted on 96 orifice plates that cover in poly-D-Lys.
These cells grow overnight at 37 DEG C in incubator, then under cool to room temperature, nutrient solution wherein uses the scavenging solution washing in 250 μ L/ holes once (10mMHEPES of 125mM Sunmorl N 60S, pH=7.3).Testing compound or blank be added to containing 40 μMs
14c-marks in the damping fluid of uric acid (54mCi/mmol), described damping fluid contains 125mM Sunmorl N 60S, 4.8mM Potassium Gluconate, 1.2mM potassium primary phosphate, 1.2mM magnesium sulfate, 1.3mM calglucon, 5.6mM glucose, 25mMHEPES, final pH=7.3.96 orifice plates at room temperature cultivate 10 minutes, then respectively clean three times with the above-mentioned scavenging solution in 50 μ L/ holes and 250 μ L/ holes successively.96 orifice plates add Microscint20 type liquid and dodges agent, plank is overnight incubation at 45 DEG C, then reading on TopCountPlateReader, and calculates IC accordingly
50.
Shown in the following list of result.
Part of compounds of the present invention is to the IC of URAT1
50value
| Compound | IC 50(hURAT1,nM) |
| Embodiment 1 compound | 8.3 |
| Embodiment 2 compound | 9.8 |
| Embodiment 3 compound | 16.1 |
| Embodiment 4 compound | 12.6 |
| Embodiment 5 compound | 14.4 |
Above-mentioned IC
50measurement result show, compound of the present invention is strong URAT1 inhibitor, can be used for preparing treatment hyperuricemia and the medicine of gout.
Claims (5)
1. there is the compound of general formula I,
Wherein, R
1be selected from H, C
1-C
5alkyl, C
3-C
6cycloalkyl.
2. the compound with general formula I that claim 1 defines,
Wherein, R
1be selected from C
1-C
3alkyl, C
3-C
4cycloalkyl.
3. the compound of Formula I that defines of claim 2, is selected from:
4. synthesize the method for the compound of arbitrary the defined general formula I of claim 1-3:
Compound II per and 4-halo butyronitrile III react in the presence of a base, obtain compound IV; Compound IV in the presence of a base with R
1x (V) is obtained by reacting compound VI; Compound VI and NaN
3at NH
4there is lower reaction in Cl, obtains product VII; VII and compound 2-halogenated acetic acids VIII is obtained by reacting product I in the presence of a base; X is selected from Cl, Br and I, and described alkali is selected from organic bases, mineral alkali; Described R
1as described in definition is corresponding as arbitrary in claim 1-3.
5. the compound of Formula I that one of claim 1-3 defines is preparing the application in treatment hyperuricemia and gout medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526292.2A CN104230833B (en) | 2014-10-07 | 2014-10-07 | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526292.2A CN104230833B (en) | 2014-10-07 | 2014-10-07 | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104230833A CN104230833A (en) | 2014-12-24 |
| CN104230833B true CN104230833B (en) | 2016-01-20 |
Family
ID=52219839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410526292.2A Expired - Fee Related CN104230833B (en) | 2014-10-07 | 2014-10-07 | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104230833B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905763A1 (en) * | 2005-06-15 | 2008-04-02 | Vladimir Evgenievich Nebolsin | N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents |
| CN102573462A (en) * | 2009-10-13 | 2012-07-11 | 维尔斯达医疗公司 | 3-substituted compounds for reducing uric acid |
| EP2581373A1 (en) * | 2010-05-11 | 2013-04-17 | Takashi Fujita | Benzo- or pyrido-imidazole derivative |
-
2014
- 2014-10-07 CN CN201410526292.2A patent/CN104230833B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905763A1 (en) * | 2005-06-15 | 2008-04-02 | Vladimir Evgenievich Nebolsin | N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents |
| CN102573462A (en) * | 2009-10-13 | 2012-07-11 | 维尔斯达医疗公司 | 3-substituted compounds for reducing uric acid |
| EP2581373A1 (en) * | 2010-05-11 | 2013-04-17 | Takashi Fujita | Benzo- or pyrido-imidazole derivative |
Non-Patent Citations (2)
| Title |
|---|
| Attila Hunyadi et al.Discovery of the fi * |
| rst non-planar flavonoid that can strongly inhibit xanthine oxidase: protoapigenone 1"-O-propargyl ether.《Tetrahedron Letters》.2013,第54卷6529-6532. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104230833A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104262277B (en) | Containing nitro and the tetrazoleacetic acid compounds of halobenzene replacement, Preparation Method And The Use | |
| CN104311442B (en) | The succinamide derivative of halo naphthalene nucleus, Preparation Method And The Use | |
| CN104292178B (en) | Containing tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104230833B (en) | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use | |
| CN104262276B (en) | Tetrazoleacetic acid compounds containing halogeno-benzene, Preparation Method And The Use | |
| CN104292123B (en) | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use | |
| CN104292175B (en) | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use | |
| CN104292176B (en) | A kind of tetrazoleacetic acid compounds containing halogeno-benzene, Preparation Method And The Use | |
| CN104292177B (en) | Nitrile group-containing and halobenzene substituted tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104311443B (en) | The naphthalene-ring containing succinamide derivative of one class, Preparation Method And The Use | |
| CN104311445B (en) | Naphthalene-ring containing succinamide derivative, Preparation Method And The Use | |
| CN104193644B (en) | The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use | |
| CN104341367B (en) | One class tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104311452B (en) | The succinamide derivative of itrile group naphthalene nucleus, Preparation Method And The Use | |
| CN104311441B (en) | Succinamide derivative, the Preparation Method And The Use of one class chloro naphthalene nucleus | |
| CN104292124B (en) | Naphthalene nucleus succinamide derivative, Preparation Method And The Use that nitrophenyl replaces | |
| CN104370841A (en) | Triazolesulfinylmalonic acid compounds as well as preparation method and application thereof | |
| CN104341364A (en) | Triazole malonic acid compounds as well as preparation method and application thereof | |
| CN104311498B (en) | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces | |
| CN104341362A (en) | Triazolesulfonylmalonic acid compounds as well as preparation method and application thereof | |
| CN104370842B (en) | The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use | |
| CN104326999B (en) | Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof | |
| CN104311444B (en) | Nitro replaces succinamide derivative, the Preparation Method And The Use of naphthalene nucleus | |
| CN104326994A (en) | Nitrile-substituted triazole sulfonyl malonate type compound, and preparation method and application thereof | |
| CN104326995A (en) | Nitrile-substituted triazole malonate type compound, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181127 Address after: 408300 Dalei Village, Chengxi Town, Dinjiang County, Chongqing Patentee after: Chongqing Shuangteng Chemical Co.,Ltd. Address before: 528000 floor 5, Pu Lan Road, Chancheng District, Foshan, Guangdong. Patentee before: Zhang Yuanqiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20211007 |